A citation-based method for searching scientific literature

Ben Sessa, Laurie Higbed, David Nutt. Front Psychiatry 2019
Times Cited: 41







List of co-cited articles
431 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Michael C Mithoefer, Allison A Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin. Psychopharmacology (Berl) 2019
129
39

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Jennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G, Wael Garas, Casey Paleos, Ingmar Gorman,[...]. Nat Med 2021
165
34


Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
628
29

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. Lancet Psychiatry 2018
159
29

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
540
26

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
524
26

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Scott F Martin, Berra Yazar-Klosinski, Yvonne Michel, Timothy D Brewerton, Rick Doblin. J Psychopharmacol 2013
213
26

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Alicia L Danforth, Charles S Grob, Christopher Struble, Allison A Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson. Psychopharmacology (Berl) 2018
71
24

Psychedelics.
David E Nichols. Pharmacol Rev 2016
528
24



MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Allison A Feduccia, Michael C Mithoefer. Prog Neuropsychopharmacol Biol Psychiatry 2018
72
21

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
479
21

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
288
21

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
421
21


Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
Lukasz Smigielski, Milan Scheidegger, Michael Kometer, Franz X Vollenweider. Neuroimage 2019
76
19

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
302
19

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
278
19

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
362
19

Human hallucinogen research: guidelines for safety.
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
385
19


MDMA enhances emotional empathy and prosocial behavior.
Cédric M Hysek, Yasmin Schmid, Linda D Simmler, Gregor Domes, Markus Heinrichs, Christoph Eisenegger, Katrin H Preller, Boris B Quednow, Matthias E Liechti. Soc Cogn Affect Neurosci 2014
155
17

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
287
17

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
141
17

Effects of Schedule I drug laws on neuroscience research and treatment innovation.
David J Nutt, Leslie A King, David E Nichols. Nat Rev Neurosci 2013
155
17

Subjective reports of the effects of MDMA in a clinical setting.
G Greer, R Tolbert. J Psychoactive Drugs 1986
261
17


Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2016
148
14



Predicting Responses to Psychedelics: A Prospective Study.
Eline C H M Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E Daws, Adam D G Hampshire, Romy Lorenz,[...]. Front Pharmacol 2018
107
14

Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.
G J H Dumont, F C G J Sweep, R van der Steen, R Hermsen, A R T Donders, D J Touw, J M A van Gerven, J K Buitelaar, R J Verkes. Soc Neurosci 2009
143
14

Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Sascha B Thal, Miriam J J Lommen. J Contemp Psychother 2018
19
31


The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
Robin L Carhart-Harris, Guy M Goodwin. Neuropsychopharmacology 2017
177
14

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy,[...]. Sci Rep 2017
197
14

Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
304
14


Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
249
12

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
176
12

Effects of psilocybin therapy on personality structure.
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
86
12

The paradoxical psychological effects of lysergic acid diethylamide (LSD).
R L Carhart-Harris, M Kaelen, M Bolstridge, T M Williams, L T Williams, R Underwood, A Feilding, D J Nutt. Psychol Med 2016
148
12

Psychedelics and connectedness.
R L Carhart-Harris, D Erritzoe, E Haijen, M Kaelen, R Watts. Psychopharmacology (Berl) 2018
71
12

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton. Lancet Psychiatry 2016
123
12

The potential dangers of using MDMA for psychotherapy.
Andrew C Parrott. J Psychoactive Drugs 2014
39
12

Potential Psychiatric Uses for MDMA.
B B Yazar-Klosinski, M C Mithoefer. Clin Pharmacol Ther 2017
34
14

Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.
Patrick C Dolder, Felix Müller, Yasmin Schmid, Stefan J Borgwardt, Matthias E Liechti. Psychopharmacology (Berl) 2018
62
12

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Marcela Ot'alora G, Jim Grigsby, Bruce Poulter, Joseph W Van Derveer, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. J Psychopharmacol 2018
68
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.